Open Access Open Access  Restricted Access Subscription or Fee Access

Stabilization of the recombinant interferon alfa-2b fusion protein

M. A. Zhuchenko, V. V. Ryabichenko, E. P. Sannikova

Abstract


Modern technologies allow to extract therapeutic recombinant fusion proteins with predictable prolongation. Although a number of technological and qualitative advantages, including the absence of further modification and purification steps, biodegradability and lack of toxic and immunogenic activities fusion proteins exhibit extreme instability during storage. Using a number of excipients resulting in a stable fusion protein through recombinant interferon alfa-2b conjugated with glycine-serine polypeptide. The obtained lyophilisate retain its physico-chemical and biological characteristics for at least 18 months. Pharmacokinetic studies have shown that the time to reach maximum concentration, half removals, half-life and bioavailability of the fusion protein was higher than in the unmodified recombinant interferon alfa-2b.

References


Bukau B, Horwich AL, The Hsp70 and Hsp60 chaperone machines, Cell, 1998, V. 6, № 92(3), P. 351 - 66.

Jiskoot W, Beuvery EC, de Koning AA, Herron JN, Crommelin DJ, Analytical approaches to the study of monoclonal antibody stability, Pharm. Res, 1990, № 7(12), P. 1234-41.

Orlov B.N., Gelashvili D.B., Zootoksinologija, Moskva, Vysshaja shkola, 1985, P. 242.

Patent US20020169125

Patent US20090298762

URL: http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM235414.pdf

J. Brange, S. Frokjaer and L. Hovgaards (eds.), Pharm. Form. and Dev. of Pept. and Prot., Taylor and Francis, London, 2000, pp. 89-112.

D. B. Volkin and C. R. Middaugh. In T. J. Ahern and M. C. Mannings (eds.), Stab. of Prot. Pharm. Part A: Chem. and Ph. Path. of Prot. Degr., Plenum Press, New York, 1992, p. 215.

Patent RU 2515913

Binder U, Skerra A, Half - Life Extension of Therapeutic Proteins via Genetic Fusion to Recombinant PEG Mimetics. Therapeutic Proteins: Strategies to Modulate Their Plasma Half-Lives, First Edition. Edited by Roland Kontermann. © 2012 Wiley-VCH Verlag GmbH & Co.KGaA

Zvjagin I.V., Hor'kov I.A., Tokarik Je.F., Metodicheskie rekomendacii po razrabotke rezhimov zamorazhivanija - vysushivanija biologicheskih preparatov, Moskva, Profizdat, 1981. P. 34.

R.Degenklbe, P.Gilligan, S.Gupta, H.Bernard, Chelating Agents Stabilize the Monomeric State of Zinc Binding Human Papillomavirus 16 E6 Oncoprotein, Biochemistry, 2003, V. 8, № 42(13), P. 3868-73.

Carpenter JF, Crowe LM, Crowe JH, Stabilization of phosphofructokinase with sugars during freeze-drying: characterization of enhanced protection in the presence of divalent cations, Biochim Biophys Acta, 1987, № 923(1), P. 109-15.

Touitou E, Alkabesa M, Memoli A, Alhaique F, Glutathione stabilizes ascorbic acid in aqueous solution, International Journal of Pharmaceutics, 1996, V. 133, № 1–2, P. 85–88.

URL: http://www.pharmapark.ru/альтевир/


Full Text: Неозаглавлен (Russian) PDF (Russian)

Refbacks

  • There are currently no refbacks.


** ** ** ** ** **

ISSN: 2073-8099

** ** ** ** ** **